

MATRIXYL®3000

Restores skin's metabolism of youth

Pal-GHK and Pal-GQPR

Function: Anti-wrinkle.

Definition:

Association of 2 palmitoylated matrikines: Pal-Gly-His-Lys and Pal-Gly-Gln-Pro-Arg.

Properties:

Matrixyl®3000 supports the activation of the cutaneous repair process, and in particular at the level of the fragile and UV-damage prone papillary dermis. Matrixyl®3000 promotes wrinkle smoothing and improves tone and elasticity.

Characteristics:

Matrikines are messenger peptides capable of regulating cell activities by interacting with their specific receptors. They activate certain genes involved in the process of extracellular matrix renewal and cell proliferation. These mechanisms become weaker and weaker with age.

Point of interest:

Matrixyl®3000 regulates the expression of progerin, a senescence marker known to accumulate with age, whereas it maintains its normal form lamin A.

INCI Name:

(Check PCPC on-line dictionary for latest INCI name) Glycerin - Aqua (Water) -Butylene Glycol - Carbomer -Polysorbate 20 - Palmitoyl Tripeptide-1* - Palmitoyl Tetrapeptide-7 Preservatives free*

*former INCI name: Palmitoyl Oligopeptide

Applications: Anti-wrinkle products.

> Formulation: Water soluble.

Recommended use level: 3%

> Patent: WO 2005/048968



www.sederma.fr E-mail: sederma@sederma.fr Copyright© 2000-2013 derma Sederma. All rights reserved.

New study reconfirms previous findings



www.matrixylinside.com



CLAIM SUBSTANTIATION

Ex vivo tests

Quantification of constituent, anchorage and cohesion proteins of the dermis and dermal-epidermal junction on skin explants (n=10, from 30 to 66 years).

In vitro tests

REGULATION OF SENESCENCE MARKERS

Study on senescent fibroblasts with Matrixyl®3000 eg 5%

• SA β-galactosidase (fluorescence method).....-56%, p<0.01 Lamin A (RNA expression)+4%, ns



In vivo tests

REPAIR OF THE PAPILLARY DERMIS

28 female volunteers aged from 51 to 72 years, mean age 59. Twice daily application of a cream containing 3% of Matrixyl®3000 for 2 months to one half of the face and the forearm (inner and UV-exposed outer forearm) against placebo.

ANALYSIS OF THE SUBEPIDERMAL LOW ECHOGENICITY BAND					
	after 2 months	Inner forearm	Outer forearm		
	THICKNESS	-9.8%/T0 up to -23%, p<0.01	-9.8%/T0 up to -33%, p<0.01		
		93% volunteers	86% volunteers		
		-11%/placebo, p<0.01	-14.4%/placebo, p<0.01		
	DENSITY	+11.4%/T0 up to +44%, p<0.01	+11.5%/T0 up to +45%, p<0.01		
		68% volunteers	82% volunteers		
		+15.2%/placebo, p<0.01	+15.1%/placebo, p<0.01		
	AGE GAIN	-3.8 years	-5.5 years		

Significant improvement of the SLEB characteristics in

just one month (thickness: -5.5%/placebo; density: +7.8%/placebo, on the inner arm) and confirmed

after two months. The ageing process is slowed down

by 1.8 years in just one month.

ANALYSIS OF THE FIBRE NETWORK

Measurements of the fibre defragmentation by confocal laser microscopy (Vivascope) on the face, next to the external eye corner.



ANTI-WRINKLE EFFICACY, SKIN TONE AND ELASTICITY

23 female volunteers aged from 42 to 67 years / Twice daily application on one half of the face of a cream containing 3% of Matrixyl®3000 against placebo, for 2 months. Assessment of the anti-wrinkle efficacy by profilometry, cutometry and photography compared to T0.

Compared to T0 (%)	Matrixyl®3000	Placebo
Surface occupied by deep wrinkles	- 39.4**	4.3ns
Main wrinkle density	- 32.9**	- 9.9ns
Main wrinkle average depth	- 19.9**	- 3.2ns
Main wrinkle average volume	- 23.3**	- 8.7*
Roughness	- 16.0**	- 1.4ns
Complexity (Lifting effect)	- 16.2**	4.2ns
Elasticity	+5.5*	4.1ns
Skin tone	+15.5**	6.5ns
ns : non significant *significant/T0 (p<0	.05) **significant	:/T0 (p<0.01)





The repairing effect of Matrixyl®3000 promotes the visible quality of the skin by decreasing the appearance of wrinkles and improving tone and elasticity.



Non-guarantee: The information in this publication is given in good faith by Sederma by way of general guidance and for reference purposes only. The information should not be construed as granting a license to practice any methods or compositions of matter covered by patents. Sederma assumes no liability in relation to the information and gives no warrantly regarding the suitability of the product and/or ingredients described by a particular use. The use made of the product and/or ingredients described by the recipient in respect of such royotact and/or ingredients described by methods and/or ingredients dues and regulations. Reproduction of all or part of this document without the express prior written consent of Sederma is strictly prohibited. 29 rue du Chemin Vert 78612 Le Perray-en-Yvelines cedex France Tel. : +33 (0)1 34 84 10 10 Fax : +33 (0)1 34 84 11 30